Thyroid Tablets — Class I drug recall D-0866-2026
Ongoing recall by VITRUVIAS THERAPEUTICS INC, reported 2026-09-23, distributed nationwide. Superpotent Drug
| Recall number | D-0866-2026 |
|---|---|
| Product type | Drug |
| Classification | Class I |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | VITRUVIAS THERAPEUTICS INC, Auburn, AL, United States |
| Recall initiated | 2026-08-21 |
| Classified | 2026-09-22 |
| Reported by FDA | 2026-09-23 |
| Distributed | Nationwide (US) |
| Quantity | 1,955 bottles |
| Reason classes | potency |
| NDC | 69680-0165, 69680-0165-00, 69680-0166, 69680-0166-00, 69680-0167, 69680-0167-00, 69680-0168, 69680-0168-00, 69680-0169, 69680-0169-00 |
| Lot numbers | 504950 |
| Expiration dates | 2026-09-30 |
Product
Thyroid Tablets, USP, 1/2 Grain (30 mg), Each tablet contains: levothyroxine (T4) 19 mcg, liothyronine (T3) 4.5 mcg, 100 Tablets, Rx only, Distributed by: Vitruvias Therapeutics, Auburn, AL 36830, Product of USA, NDC 69680-166-00.
Reason for recall
Superpotent Drug
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0866-2026. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-29. Not affiliated with or endorsed by FDA. Not medical or legal advice.